

CLAIMS:

1. A modified oligonucleotide according to the following chemical structure:




(SEQ ID NO: 3590), or a salt thereof.

2. A modified oligonucleotide according to the following chemical structure:




(SEQ ID NO: 126), or a salt thereof.

3. A modified oligonucleotide according to the following chemical structure:




(SEQ ID NO: 1045), or a salt thereof.

4. A modified oligonucleotide according to the following chemical structure:




(SEQ ID NO: 2552), or a salt thereof.

5. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 3190), or a salt thereof.


6. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 3638), or a salt thereof.


7. The modified oligonucleotide of any of claims 1-6, which is the sodium salt or the potassium salt.

8. A modified oligonucleotide according to the following chemical structure:




(SEQ ID NO: 3590).

9. A modified oligonucleotide according to the following chemical structure:




(SEQ ID NO: 126).

10. A modified oligonucleotide according to the following chemical structure:




(SEQ ID NO: 1045).

11. A modified oligonucleotide according to the following chemical structure:




(SEQ ID NO: 2552).

12. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 3190).

13. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 3638).

14. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation: ^{m}Ces ^{m}Ceo ^{m}Ceo Geo Tes Ads Tds Tds ^{m}Cds ^{m}Cds Tds ^{m}Cds Tds Tds Ads ^{m}Ceo ^{m}Ceo Aes Tes ^{m}Ce (SEQ ID NO: 3590), wherein,

A = an adenine nucleobase,

^{m}C = a 5-methylcytosine nucleobase,

G = a guanine nucleobase,

T = a thymine nucleobase,

e = a 2'-MOE sugar moiety,

d = a 2'-β-D deoxyribosyl sugar moiety,

s = a phosphorothioate internucleoside linkage, and

o = a phosphodiester internucleoside linkage.

15. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation: Ges ^{m}Ceo Aeo ^{m}Ceo Ges Gds Tds Ads Tds Tds Ads Gds Tds Gds Tds ^{m}Ceo Teo Tes ^{m}Ces Ae (SEQ ID NO: 126), wherein,

A = an adenine nucleobase,

^{m}C = a 5-methylcytosine nucleobase,

G = a guanine nucleobase,

T = a thymine nucleobase,

e = a 2’-MOE sugar moiety,

d = a 2’-β-D deoxyribosyl sugar moiety,

s = a phosphorothioate internucleoside linkage, and

o = a phosphodiester internucleoside linkage.

16. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation: Ges ^{m}Ceo Teo Teo ^{m}Ces Tds ^{m}Cds Ads Ads Ads Tds ^{m}Cds Ads Gds Gds Teo Geo Tes Aes mCe (SEQ ID NO: 1045), wherein,

A = an adenine nucleobase,

^{m}C = a 5-methylcytosine nucleobase,

G = a guanine nucleobase,

T = a thymine nucleobase,

e = a 2’-MOE sugar moiety,

d = a 2’-β-D deoxyribosyl sugar moiety,

s = a phosphorothioate internucleoside linkage, and

o = a phosphodiester internucleoside linkage.

17. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation: Ges ^{m}Ceo ^{m}Ceo Teo Tes Tds Ads Tds Ads Ads ^{m}Cds Tds Tds Tds Tds ^{m}Ceo Teo Tes Tes ^{m}Ce (SEQ ID NO: 2552), wherein,

A = an adenine nucleobase,

^{m}C = a 5-methylcytosine nucleobase,

G = a guanine nucleobase,

T = a thymine nucleobase,

e = a 2’-MOE sugar moiety,

d = a 2’-β-D deoxyribosyl sugar moiety,

s = a phosphorothioate internucleoside linkage, and

o = a phosphodiester internucleoside linkage.

18. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation: Tes Teo ^{m}Ceo Aeo Ges Tds Tds Tds Ads Gds Tds Tds Gds ^{m}Cds Ads Geo ^{m}Ceo ^{m}Ces Aes Te (SEQ ID NO: 3190), wherein,

A = an adenine nucleobase,

^{m}C = a 5-methylcytosine nucleobase,

G = a guanine nucleobase,

T = a thymine nucleobase,

e = a 2'-MOE sugar moiety,

d = a 2'-β-D deoxyribosyl sugar moiety,

s = a phosphorothioate internucleoside linkage, and

o = a phosphodiester internucleoside linkage.

19. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation: Tes ^{m}Ces Aes Geo Tes Tds Tds Ads Gds Tds Tds Gds ^{m}Cds Aeo Ges ^{m}Ces ^{m}Ce (SEQ ID NO: 3638), wherein,

A = an adenine nucleobase,

^{m}C = a 5-methylcytosine nucleobase,

G = a guanine nucleobase,

T = a thymine nucleobase,

e = a 2'-MOE sugar moiety,

d = a 2'-β-D deoxyribosyl sugar moiety,

s = a phosphorothioate internucleoside linkage, and

o = a phosphodiester internucleoside linkage.

20. A population of modified oligonucleotides of any of claims 1-13, or a population of oligomeric compounds of any of claims 14-19, wherein all of the phosphorothioate internucleoside linkages of the modified oligonucleotides are stereorandom.

21. A pharmaceutical composition comprising the modified oligonucleotides of any of claims 1-13, the oligomeric compounds of any of claims 14-19, the population of modified oligonucleotides of claim 20, or the population of oligomeric compound of claim 20, and a pharmaceutically acceptable diluent.

22. The pharmaceutical composition of claim 21, wherein the pharmaceutically acceptable diluent is artificial cerebrospinal fluid or phosphate-buffered saline (PBS).

23. The pharmaceutical composition of claim 22, wherein the pharmaceutical composition:

a) consists essentially of the modified oligonucleotide or the oligomeric compound and artificial cerebrospinal fluid;

b) consists essentially of the modified oligonucleotide or the oligomeric compound and PBS;

c) consists essentially of the population of modified oligonucleotides or the population of oligomeric compounds and artificial cerebrospinal fluid; or

d) consists essentially of the population of modified oligonucleotides or the population of oligomeric compounds and PBS.